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Summary.-Tumour antigen-induced inhibition ofleucocyte adherence was modified
for use in glass test tubes (Tube LAI assay) for the study of cell-mediated anti-
tumour immunity to human malignant melanoma. Peripheral blood leucocytes
(PBL) of 20 out of 25 patients (80%) with active malignant melanoma responded to
an extract of malignant melanoma with LAI, whereas only 4.5%o of 475 control
subjects showed a response. The malignant melanoma patients reacted to both
allogeneic and autologous extracts of malignant melanoma which indicates a
common cross-reacting antigen. Malignant melanoma patients did not respond to
unrelated tumour extracts. The LAI was mediated by PBL (monocytes) " armed"
with cytophilic anti-tumour antibody specific for the sensitizing tumour antigen.
The anti-tumour response of the malignant melanoma patients was dependent on
the stage of the cancer, and 11 out of 13 Stage I patients had a positive NAI, whereas
patients with disseminated cancer had decreased response. The diminished LAI
in patients with large tumour burdens appeared to be the result of release of tumour
antigen systemically. Also, surgery and chemotherapy depressed LAI. Although
LAI was depressed after surgical excision of the cutaneous melanoma, most patients
showed LAI 1-3 months later. Tumour-free melanoma patients monitored for one
year by the Tube LAI assay showed a decline in their anti-tumour immunity 5-6
months after surgery. The NAI was low or negative after the 8th post-surgical
month in tumour-free patients. Patients with residual malignant melanoma
showed persistent or recurrent LAI after the 8th post-surgical month. LAI reactivity
monitored after " curative " surgery for malignant melanoma may assist in deter-
mining whether the patient is tumour-free or has a recurrence.
Abbreviations used are:
CMI, Cell-mediated immunity;
IDTIC, 5-(3, 3-Dimethyl-1 -triazenoimida-
zole-4-carboxamide;
LAI, Leucocyte adherence inhibitioni
NAT, Non-adherence index;
PBL, Peripheral blood leucocytes;
PBS, Phosphate-buffered saline.
EVIDENCE for the existence of a host
immune response to malignant melanoma
has increased during the last few years
(Lewis et al.,1969; Oren and Herberman,
1971; Cochran et al., 1972; deVries,
Rumke and Bernheim, 1972; HellstrCm
et al., Heppner et al., 1973; and Hollins-
head et al., 1974). Distinctive cellular
and humoral immune responses are des-
cribed (Morton et al., 1968; Lewis et al.,
1969; Currie et al., 1971; Fossati et al.,
1971; Nairn et al., 1972; Hellstrom and
Hellstrapm, 1973; and Bodurtha et al.,
1975). Moreover, quantitative changes
in the cellular and humoral immune
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responses to tumour are observed with
tumour progression (Lewis et al., 1969;
Morton, Eilber and Malmgren, 1971;
deVries et al., 1972; Cochran et al., 1973;
Hellstrom et al., 1973; and Hellstrom and
Hellstrom, 1973).
Halliday and Miller (1972) developed
an assay of cell-mediated anti-tumour
immunity, called leucocyte adherence
inhibition (LAI). This assay is based on
the findings that non-sensitized leucocytes
from both patients with cancer and control
subjects adhere to glass, whereas leuco-
cytes from cancer patients but not from
control subjects, when mixed in vitro with
antigenic extracts of tumours of the same
histologic type, undergo a diminution in
their normal adherence to glass surfaces.
In a rat model, Holan et al. (1974) des-
cribed a modified version ofthe LAI assay
that was performed in test tubes and the
number of non-adherent cells was mea-
sured. We modified the LAI procedure
of Holan et al., and studied the anti-
tumour immunity to human breast cancer
(Grosser and Thomson, 1975).
Recently Halliday et al. (1975) reported
the results of the LAI assay in 75 patients
with malignant melanoma. We studied
LAI in 33 patients with malignant
melanoma by the LAI assay in test tubes
(Tube LAI assay), an assay that appears
to differ only methodologically. Never-
theless, there are important differences in
the results in the two studies. In the
present study we show that LAI depends
on the extent of the malignant melanoma,
and patients with large tumour loads were
unreactive. In addition, surgery and
chemotherapy altered LAI. Further-
more, when the kinetics of LAI were
monitored during the year after excision
of the primary melanoma, LAI reactivity
was generally undetectable 6-8 months
post-surgery in "cancer-free" patients.
MATERIALS AND METHODS
Subject studies-.Heparinized blood
samples were obtained by venepuncture from
33 patients with malignant melanoma.
Thirty patients had cutaneous melanoma
and 3 patients had ocular melanoma (one
primary and 2 secondary). The group of475
control subjects was composed of 119 patients
with benign breast disease, 153 patients with
adenocarcinoma of the breast, 162 elective
surgical patients with benign disease and 33
patients with other cancers. In addition, 8
healthy West Indian negroes were tested.
Malignant melanoma of the skin was
staged as follows: Stage I a localized
primary malignant melanoma confined to the
skin or eye; Stage 11-regional lymph node
metastasis or local recurrence of tumour in
skin or lymph nodes; Stage III-distant
metastasis.
In some instances, patients with Stage I
melanoma were assayed after punch biopsy
of the suspect skin lesion, but always before
definitive wide surgical excision and skin
grafting. Patients with Stage II melanoma
were assayed prior to complete surgical
excision ofthe malignant melanoma. Patients
with Stage III melanoma had previously had
their lesion excised and were presenting with
recurrent tumour when they were assayed.
In addition, there were 8 patients who had
had a cutaneous malignant melanoma (Stage
I or II) excised at least a year earlier and
they were clinically cancer-free when they
were tested for the first time.
All subjects who gave blood samples had
the nature of the test explained to them and
verbal consent was obtained.
Tumour extracts.-Malignant melanoma
samples were received at operation and
placed in a sterile container. Appropriate
amounts of the tumours were taken for
routine pathology. Fatty and fibrous tissues
were dissected away, and the specimen was
finely minced with sharp scissors in ice-cold
PBS (001 M phosphate buffer, 0415 M saline)
at pH 7-3. The resulting material was
homogenized for 10-15 min in 5 volumes of
PBS at 40,000 rev/min in a Virtris 45 homo-
genizer. The homogenate was centrifuged
at 20,000 g for 30 min and the supernatants
were stored at -40°C in 2-ml aliquots.
Extracts of other tumours were prepared in
an identical fashion. The protein concen-
trations of the stock extracts of malignant
melanoma, breast cancer, and other tumours
were 6-8-5 mg/ml. All tumour extracts were
ofsimilar protein concentrations. LAI assay
in test tubes was performed with a stock
extract composed of a pool of 3 different
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melanoiiia tumour extracts, whereas in-
dividual breast or bladder tumour samples
ere employed as the non-specific control ex-
tracts.
For use in the assay, the concentrated
stock extracts were thawed in a water bath at
20°C and a sample was diluted with Medium
199 (Gibco, Grand Island, N.Y.). An 0'1-ml
aliquot ofthe diluted stock extract was added
to certain designated tubes containing the
standard quantity of 106 PBL in 0-1 ml of
Medium 199.
Antigen-idnduced leucocyte adherence inhibition
(LAI) to glass in test tubes (Tube LAI assay).
The LAI assay in test tubes was performed as
previously described by Grosser and Thomson
(1975). In brief, 20-ml samples of heparin-
ized venous blood were obtained in tw o 10-ml
green stopper vacutainer tubes (Beeton,
Dickinson & Co., Mississauga, Ont.) and
incubated vei-tically at 37°C for 1 h. The
r-esulting leucocyte-rich plasma fraction was
aspirated and centrifuged at 200 9 for 5 min.
The cell-free plasma was then removed and
discarded. 'T'he cell button as suspended
in an ice-cold, isotonic, Tris-buffered NH4C1
solution (Boyum, 1968) by repeated pipetting,
and was left for 15 min at 4°C in order to lyse
contaminating erythrocytes. This procedure
was terminated by the addition of 3 ml of
Medium 199.
The cells were centrifuged as described
above, and the supernatant was removed and
discarded. The cells were then washed
twrice with 10 ml of Medium 199, and resus-
pended at a concentration of 107 cells/ml of
Medium 199.
Antigen-induced inhibition of leucocyte
adherence to glass wN-as tested in 20-ml,
16 x 150 mm test tubes (Kimax, Fisher
Scientific, Montreal, Canada). Aliquots of
01 ml of a PBL suspension (107/ml) were
placed in the test tubes. Then either 0-1 ml
of Medium 199 or 01 ml of specific tumour
extract or unrelated tumour extract was
added to each tube. The mixture was
brought to a final volume of 0-5 ml in all
tubes by the addition of the appropriate
volume of Medium 199. The suspension in
each tube was thoroughly mixed with a
Pasteur pipette and the tubes were then
incubated horizontally, so that the contents
covered 3 of the lower surface of each tube.
The tubes were incubated at 37°C in a humidi-
fied atmosphere of 50o CO2 in air. After 2 h
ofincubation, the tubes were placed vertically
and their contents were agitated with a
Pasteur pipette just before counting. The
number ofnon-adherent cells/ml was counted
in an improved Nebauer haemocytometer.
All assays were in triplicate. Incubation of
the cells in the absence of tumour extract
beyond a 2-h period did not produce
appreciably increased adherence ofleucocytes
to glass. Hence a 2-h incubation period was
chosen.
The results were expressed as:
Non-adherence index (NAI)
= Non-adherent cells in presence of
specific antigen
-Non-adherent cells in presence of
non-specific antigen
Non-adherent cells in presence of non-
specific antigen
x 100
Since this aspect of the study involved
delineating the reactivity of patients to
malignant melanoma, the specific antigen
was an extract of malignant melanoma, while
the unrelated antigens were extracts of breast
cancer and bladder cancer. Extracts of
other tumours, such as cancers of ovary,
bladder and lung, were prepared in a similar
manner and also employed as the non-
specific control antigen or for the study ofthe
specificity of LAI.
Titration of tumour extracts. The stock
tumour extracts were diluted and added to
the test tubes at different protein concen-
trations. Figure 1 shows that protein
concentrations of approximately 110 ,tg and
120 ,ug for malignant melanoma and breast
tumour extracts respectively appear to be
optimal. The tumour extracts were used
throughout this study at these dilutions.
In this study, other tumour extracts were
used at approximately 100 ,ug protein/test
tube. Protein determinations were per-
formed by the method of Lowry et al. (1963)
using bovine serum albumin as a standard.
' Arming " of control cells by serun fromn
reactive melanoma patients.-Blood was taken
from melanoma and breast cancer patients
and control subjects and immediately stored
at 4°C. After overnight retraction of the
clot, the serum was separated and stored at
-400C.
Patients with Stage I or Stage II malig-
nant melanoma and breast cancer had their
serum assayed for ' arming" in the LAI
assay. Before use, the serum was diluted
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1 1 w Nith Medium 199, and 0 5 ml of the
above solution was added to 107 PBL from
healthy control subjects, suspended in 0 5 ml
of Medium 199. The mixture was then
incubated for 45-60 min at 37°C in 50o CO2
atmosphere with intermittent shaking of the
tubes. At the end of this period, the cells
were spun dow,n, washed 3 times with
Medium 199 and then plated separately in
test tubes with Medium 199 alone, breast
cancer and melanoma extracts. PBL from
healthy subjects were also tested in the LAI
assay after incubation with 199 alone, with
serum from control subjects and from
patients with metastatic disease who were
non-reactive.
Serum IgG was isolated by the batch
method of Reif (1969) with DEAE cellulose.
Thie purity of the isolated IgG was examined
by immunoelectrophoresis with anti-whole-
human serum.
RESULTS
Specificity of LAI in test tubes
When PBL from malignant melanoma
patients or control subjects are incubated
in glass test tubes without antigen for 2 h,
generally less than 10% of the cells are
non-adherent. The addition of foetal
calf serum (FCS) to the incubation
medium inhibited the adherence of4-43O
of the leucocytes of control subjects and
the percentage non-adherence varied with
the concentration of FCS (Table I).
Similarly, the addition of tumour extract
to non-sensitized PBL inhibited the
adherence of 18-38%0 of the leucocytes
and the number of non-adherent leuco-
cytes increased with the more concentrated
tumour extract (Table I and Fig. la, b).
To achieve the optimum assay condi-
tions, that is, the maximum specific
inhibition of leucocytes adherence with
the least non-specific inhibition, the
antigen extracts were first tested at
different protein concentrations with
leucocytes from control subjects and then
with leucocytes from patients with
corresponding tumour (Fig. la, b). A
dilution of malignant melanoma and
non-specific control extract (breast or
bladder) that inhibited the adherence of
approximately 50 leucocytes from control
subjects was chosen for assay ofmalignant
melanoma patients.
Figure la, b show that in the control
subjects the number of non-adherent cells
TABLE I. Inhibition of Adherence of Non-sensitized Leucocytes by Protein
in the Incubation Medium
Non-sensitizcd leucocytes
AMaterial in incubation medium Number of non-adherent cells* 0 Non-adherencet
199 alone 16 20 18 9
100% FCS 93 79 85 43
100 FCS 37 42 41 20
0-1% FCS 25 24 24 12
0-0100 FCS 8 7 9 4
MTelanioma extract
1:4 79 80 70 38
1 :6 56 59 65 30
1 :8 49 59 60 29
1: 16
Breast, cancer extract
1 : 4
1 :6
1 : 8
1: 16
42
a5
60
48
40
41
65
52
53
29
42 21
54
56
49
39
29
28
25
18
* Per Haemocytometer test tube.
t % Non-adherence is calculated on the basis that if there were 106 non-adhersnt cells in the test tubes in 0 5 ml of medium, then 200 cells would be counted in the haemocytometer. If in the test tubes an average of 50 non-adherent cells is counted, then the % non-adherence
is:
200 x 100 = 25%.
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Fi(e. la, b. Titration curves of the tumour extracts. Upper graph of Fig. la( shows the number of
non-a(lherent leucocytes of a control subject at different protein concentrations of the extracts.
The non-adherence index (NAI) is calculated for the melanoma tumour extract at each dilution of
the tumour extracts. Lower graph of Fig. la shows the number of non-adherent leucocytes of a
melanoma patient at different protein concentrations of the ttumour extracts. NAI for the
melanoma antigen is calculated for each dilution. Fig. lb shows the number of non-adherent
leucocytes of another control subject and the NAI for both the melanoma and breast extracts.
The lower graph of Fig. lb shows the number of non-adherent leucocytes of a breast cancer patient
at dlifferent protein concentrations of the tumour extracts and the NAI for breast cancer. *,
Number of non-adherent cells in presence of melanoma extract. O, Number of non-adherent
cells in presence of breast cancer extract. .......... -, NAI to melanoma extract.
NAI to breast cancer extract.
with the melanoma or breast tumour
extracts was similar at the same protein
concentrations of the tumour extracts.
To express the difference in reactivity to
the 2 tumour extracts a non-adherence
index (NAI) is calculated as described in
"Materials and Methods".
Figure la shows the NAI ofthe control
subject to the melanoma extract. The
NAI was never greater than 30 with
protein concentrations ranging from 25 to
300 ,ag. Figure lb shows the NAI of
another control subject to both the
melanoma extract and the breast tumour
extract. The NAI to the melanoma
extract at a protein concentration of
50 ,tg was slightly greater than 30 but
the remaining values were less than 30.
In comparison, Fig. la shows the number
of non-adherent cells of a melanoma
patient to the two extracts and the NAI.
At almost all protein concentrations the
NAI of the melanoma patient was greater
thail 30. At 50 ,tg protein the NAI was
> 100. Nevertheless, protein concen-
trations < 75 /tg were never used since
there were too few non-adherent cells to
give consistent and reliable differences
in reactivity to the 2 tumour extracts.
Figure lb shows the reactivity of a
breast cancer patient to the breast cancer
antigen. The NAI peaks to approxi-
mately 40 in this patient with the tumour
extracts used at protein concentrations of
approximately 110 pg. Although the
NAI of this breast cancer patient is not
high, calculation of the NAI to the breast
cancer extract of the control subject in
Fig. lb shows throughout values of
approximately 0 to 20.
Also, Fig. la, b show that at the higher
protein concentrations of the tumour
extracts the specificity of the leucocyte
non-adherence response was diminished or
lost. We have observed that the titration
curves of different reactive patients vary.
G)
c
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Nevertheless, the leucocytes of most
patients show LAI with protein concen-
trations of the tumour extracts of 75 to
150 ig. Frequently, a difference in re-
activity to the 2 tumour extracts was not
observed with tumour extracts at protein
concentrations less than 75 jig or greater
than 200 ,Ig.
Table II shows the results when the
PBL of 6 control subjects, 3 malignant
melanoma patients and 2 breast cancer
patients were assayed with a dilution of
melanoma and breast cancer tumour
extract at 110 pig and 120 lig protein/tube
respectively. PBL from malignant
melanioma patients incubated with mela-
noma extract had leucocyte non-adherence
ranging from 78 to 92 cells, whereas the
same cells incubated with breast cancer
extract showed 42-46 cells to be non-
adherent. Control subjects showed a
non-adherence in the range of 34 to 78
leucocytes and the responses to the
malignant melanoma and control breast
tumour extracts were, in the same patient,
usually similar. Calculation of NAI for
the control subjects shows a value less
than 30. By contrast, the patients with
malignaant melanoma and breast cancer
show NAI > 30 to their respective
tumour extracts (Table II).
A constant feature of the assay is the
variabilitv in the number of non-adherent
leucocytes in any single test subject.
Moreover, the same test subjects fre-
quently show different degrees of
leucocyte adherence when tested on
separate days. It is essential, therefore,
to compare difference in non-adherence
between a specific and non-specific tumour
extract rather than the absolute number
of non-adherent cells.
Reproducibility of repeat assays in mela-
noma patients
In many instances, patients with
melanoma were re-assayed prior to
surgery. Table III shows that all
patients who had LAI on the first tube
LAI assay also showed reactivity when
the assay was repeated. Some patients
with malignant melanoma had surgery
before a repeat test was performed.
Nevertheless, Fig. 4 also shows that after
recovery from the immunodepression
produced by surgery, the patients with
LAI before surgery display LAI again.
Cross-reactivity with different malignant
melanoma extracts
Table IV shows that the NAI was
similar whether the PBL of patients with
malignant melanoma were exposed to
allogeneic or autochthonous melanoma
extracts. It is of interest that 3 of the 4
patients showed a slightly stronger
TABLE II. Antigen-mediated LAI in Glass Test Tubes*
Mfean number of non-adherent cells in
presence of
Diagnosis
MAelanoma
AMelanoma
Melanoma
Breast cancer
Breast cancer
Bowel cancer (Negro)
LLnTIg cancer
Ovarian cancer
Bladder cancer
Cholec'stitis
Iniguinial hernia
Malignant
melanoma
anitigen
78
92
82
40
70
54
64
78
6i2
48
.14
Breast
cancer
antigen
44
46
42
58
120
56
54
72
48
48
36
No
antigen
16
10
18
20
26
12
18
36
26
18
4
* Examples of Tube LAI assays performedt at separate times ovei- 6 moniths.
t NAI greater than 30 was considered significant.
+ NC -- Not calcuilate(l.
NAI to t
Malignant Breast
melanoma cancer
77 NC+
100 NC
95 NC
NC 45
NC 71
-3 ,3
14 -15
8 -7
29 -22
0 0
-6 5
Patient
GLC
AIT
NF
BW
RG
VTG
LSF
LB
DF
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TABLE 1II. Reproducibility of Repeat
Tube LAI Assays for Reactivity in
Melanoma Patients
NAI*
Patient Pre-surgical
1 2
A 32 41
F 84 78
F 38 48
H 50 88
1 3(0 33
L 70 78
T 70 44
G 1 5
c
* Assays I an(i 2 within 3 days ol
TABLE IV. NAI of Leucocy
nant Melanoma Patie
Different Extracts of
Melanoma
extrac
mel
Patient, (liagniosis 'McK
Malignant melainoma MNcK 1000
MNalignant melanoma LC 50
Malignant melarloma DC 40
Ataligniant melanoma 10 185
Control stubject 27
* NAT valtue gireater thani 30
signiificantt.
the presence of tumour-specific trans-
plantation antigens in individual tumour
extracts cannot be excluded.
Pos-surgi Lack of reactivity with unrelated tumtour Post-surgical
1 2 extracts
When other tumours were used as the 82 80 non-specific control antigen, the results
were similar to those with the breast
cancer extract. In particular, a bladder
cancer extract was tested against malig-
nant melanoma and bladder cancer
50 68 patients and control subjects. XVith
f each other. leucocytes from patients with malignant
melanoma, LAI was shown to the
tes of Malig- melanoma extract, but not to the bladder
nts to 4 cancer extract (Table V). Moreover, the
Malignant leucocytes of the bladder cancer patients
showed reactivity to the bladder cancer
NAI* to extract but not to the melanoma extract
-t ofmalignant (Table V). The leucocytes from control
lanoma from subjects showed no reactivity to either
-LC-DC' 10 tumour extract. Furthermore, leuco-
85 72 cytes from 2 malignant melanoma patients
68 30 57 that were reactive to malignant melanoma
106 86 70 extract showed no evidence of cross-
157 57 33 reactivity to tumour extracts of lung,
bladder or ovary when assayed by the LAI
was considlered in test tubes (Table VI).
reaction to their own tumour in com-
parison to the allogeneic tumour. The
only patient who showed a low reactivity
to autochthonous tumour extract was
tested against her own tumour when she
had advanced cancer and her NAI had
decreased. Although the LAI assay
detects principally a cross-reactivity
between all mnelanoma tumour extracts,
Immunologically-specific ' arming" with
serum
Previous experiments by Grosser and
Thomson (1975) with the tube LAI assay
suggested that the LAI was not mediated
by lymphokines released by lymphocytes
interacting with the tumour antigen. In
fact, the results suggested that the PBL
reacted directly with the tumour antigein
TABLE V. Tube LAI Assay to Malignant Melanoma with Bladder
Cancer Extrcact as the Non-specific Antigen
NAI to melanioma
No. No. -- A
Patient diagnosis tested positive Mean Ranige
AMalignant melanoma 6 6 85 41-133
Bladder cancer 15 0 22 25-(- 47)*
Benign (lisease 4 0 9 0-15
Other malignaincy 2 0 16 14-18
*Calculatecd with bladdei extract as specific antigen and melanioma tumour
extract as non-specific antigen, 9 out of 15 patients with bladder cancer had NAI
> 30, anid mean NAI 38, range 90-(- 20).
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and the reactive cell was a peripheral
blood monocyte (Grosser and Thomson,
1975; Grosser et al., 1976). Hence,
TABLE VI. NAI of Leucocytes of Malig-
nant Melanoma Patients to Malignant
Melanoma Extract Using a Panel of
Different Non-specific Tumour Extracts
Br east
tumour
71
80
0
Control extracts
Lung Bladder Ovarian
tumour tumour tumoui'
37 130 34
32 127 35
-21 3 -18
leucocytes of control subjects that dis-
played no LAI were pre-incubated with
appropriate sera and were then washed
prior to plating into the tube LAI assay.
Table VII shows that incubation of
control leucocytes with serum from
reactive patients with malignant inela-
noma or breast cancer resulted in specific
LAI to the appropriate tumour extract.
Consequently, the reactivity of leucocytes
" armed " with serum from reactive
patients was similar to the leucocyte
reactivity of the serum donors. Con-
versely, Table VII shows that the serum
from patients with metastatic malignant
melanoma or breast cancer, whose leuco-
cytes failed to react in the tube LAI assay,
did not " arm " normal leucocytes.
IgG isolated from the serum ofreactive
patients by DEAE cellulose " armed "
normal leucocytes to the appropriate
tumour extract (Table VII).
TABLE VII. Immunologically-specific " Arming " of Normal Leucocytes with Serum
from Reactive Patients with Malignant Melanoma
Donor of Donor leucocytes
leucocytes preincubated with
an(d (NAI)* serum from
Control (4) Reactive melanoma§
Reactive breast§
Normal
Control (- 13) Reactive melanoma
Normal
Control (7) Reactive melanoma
Reactive breast
Normal
Control (14) Reactive melanoma
Reactive breast
Normal
Control (- 1) Non-reactive melanomall
Non-reactive breast!I
Control
IgG isolated by DEAE
chromatography+
Control (-7) Reactive melanoma
Reactive breast
Normal
Control (-2) Reactive melanoma
Reactive breast
Normal
NAI*
of
serum
donor
87
84
S
48
-2
60
47
10
49
64
15
5
4
-7
78
71
-5
65
51
3
Number of non-adherentt cells
:3
:3
8
4
7
4
4
6
3
Melanoma
extract
)6 113 1
32 65
71 70
9 37
30 20
4 75
.3 44
35 36
18 60
.8 45 4
L5 40
4 59
1 60
,9 40 4
78
60
54
64
42
40
72
61
55
70
40
45
I1
67
66
40
27
78
49
40
74
43
50
56
66
40
73
57
58
70
41
47
59
129
64
14
31
44
71
38
50
72
40
55
58
43
53
77
58
52
58
49
Breast
tumour
extract
65
115 ]
L 69
18
27
45
69
41
42
73
42
50
59
44
54
79
59
49
59
47
69
110
75
24
23
41
65
:38
45
73
:39
45
60
48
59
84
58
42
59
44
NAI** to
C--- --~Brs
B3rea.st,
cancer
83
0
51
6
62
11
-5
13
52
5
44
8
Melanoma
69
0
107
-5
84
-6
54
13
12
- 11
35
_ 5
40
-6
* NAI calculated from the number of leucocytes showing non-adherence in the presence of tumour
extracts of melanoma and breast.
t Tests were done in triplicate.
I IgG was isolated from serum by batch DEAE cellulose chromatography and t,he isolated IgG was
concentrated to 12 mg/ml protein and used at a dilution of 1: 2.
§ Reactive melanoma or reactive breast: serum from patients with melanoma or breast 'cancer whose leucocytes reacted in the tube LAI assay.
[l Non-reactive: serum from patients with large tumour burdens whose leucocytes did not react in the tube LAI assay.
** NAI to melanoma or breast cancer extract as described in Material and Methods.
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200
180
160
140
z
120
- 100
80
v
0
40 20
0
S
0
8..
0@~~~~~~
0
: S
. S
. -..-....-..-........._......_
0
* 0
*0
* @0
Stage I Stage II Stage III Dis. Free
>1 yr.
Fi(e. 2.-Patients with a diagnosis of malignant melanoma who were assayed by LAI in test tubes.
Staging is as described in 'Materials and Methods'. NAI > 30 was regarded as positive.
Clinical features of LAI in test tubes in (TableVIII). Inthis seriesofpatientsand
malignant melanoma with these tumour extracts, NAI > 30
The results in 33 patients with histo- was selected as significant on the basis
logically proven malignant melanoma are that this value best separated the popula-
shown in Fig. 2 and Table VIII. LAI tion of malignant melanoma patients and
occurred with PBL from 22 of the 33 control subjects. Table VIII shows that
(66%) malignant melanoma patients of the 475 control subjects, 21 (4*5%0) had
TABLE VIII. Summary ofPatients Tested by LAI in Test Tubesfor Reactivity
to Melanoma Extract
Patients studied Total Positive* Mean NAI
Malignant melanoma
Stage I 13 11 61
Stage II 7 7 103
Stage III 5 2 32
Disease-free > one year 8 2 22
Halo nevus 1 1 31
Control subjects
Pre-surgical benign disease 162 5 -2 Benign breast disease 119 4 J
Healthy West Indian Negroes 8 0 5
Unrelated cancer:
Breast cancer 153 10 -21
Lung 6 0
Bowel 5 1
Bladder 15 0 . -4
Ovary 5 0
Thyroid 2 1 J
t NAI > 30.TUBE LAI ASSAY IN MALIGNANT MELANOMA
NAI*
MNelaiomat
Mlelanoma ascitic
extract fluid
57
-20
31
30
*Calculatedl with melanoma extract or melanoma
ascitic fluid as specific arntigen and(l ovarian tumour
extract as no)n-specific aintigen.
t Melanoma ascitic fluid was tested neat an(d at a
I: 2 (lilutioll.
NAI > 30. Some of these 21 positive con-
trol subjects were re-assayed and 2 demon-
strated continued significant LAI to the
melanoma tumour extract. The mean
NAI of the control subjects was close to
zero with the melanoma extract as the
specific antigen and breast cancer extract
as the non-specific antigen (Table VIII).
Control patients with cancers other than
malignant melanoma did not show LAI
when tested with a melanoma extract.
In comparison, the malignant melanoma
23(
21(
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130
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Before Surgery After Surgery
FIG. 3. NAI ofmalignant melanoma patients before
and 1-2 weeks after surgery.
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patients tested prior to surgical excision of
the melanoma had a mean NAJ of 61, 103,
and 32 for Stage 1, 11 and III cancer,
respectively, and this was significantly
different from the control group
(P < 0-001).
LAI with stage of malignant melanoma
Depending on the stage oftheir cancer,
the PBL of the malignant melanoma
patients had different degrees ofreactivity
in the LAI assay (Fig. 2). Of the 13
patients with Stage Imalignant melanoma,
11 showed reactivity in the LAI assay,
although many had small cutaneous
lesions. Their mean NAI was 61. Two
patients had NAI < 30. One patient
had a 3 x 5-mm malignant melanoma of
the conjunctiva without any invasion, and
the other patient had a 1 x 1.2-cm lesion
of the leg. All patients with Stage II
malignant melanoma showed LAI and
their mean NAI of 103 was the highest of
all the stages.
By contrast, 3 of the 5 patients with
Stage III malignant melanoma did not
show LAI. Moreover, the positive NAI
of one of the patients became negative as
the tumour burden increased. The other
Stage III cancer patient with a positive
NAI had a solitary liver metastasis
resected and the patient is clinically
cancer-free after 16 months. The mean
NAI of 32 of the Stage III patients was
the lowest for patients with active cancer.
Finally, 8 patients, all of whom had
previously had Stage I or II malignant
melanoma resected at least one year
previously and were clinically free of
cancer, were assayed by LAI in test tubes.
Six of the 8 patients had NAI of 30 or
less and the remaining 2 patients had
NAI of 38 and 40. These patients, with a
history of malignant melanoma who were
clinically free of cancer, had a mean NAI
of 22 (Fig. 2, Table VIII).
LAI before and after surgery
PBL from malignant patients were
studied in the LAI assay before and after
surgical excision of the malignant mela-
TABLE IX. Effect of Melanoma Ascitic
Fltid on LAI
Patiei-t diagnolsis
AMalignanit melanoima
Control stubject
z
-u x
0 -0 -c
0
z
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FIG. 4. Sequential determination of NAI of mialiginaint melanioma patienits. All patienits showvn
were clinically tumour-free one year after tumInour excisioln. Patient w-ith Stage I melanioma
; patient with Stage II melanoma - -; patienit xvith Stage fIti melaim)ma -
noma. Figure 2 shows that all patients had
a marked fall in their NAI to melanoma
extract in the first and second post-
operative week. In general, patients
showed a recovery of their LAI to mela-
noma extract (Fig. 4). Not shown in
Fig. 4 are 2 patients withStage Imalignant
melanoma, who had LAI before surgery
but, when tested 6-8 weeks after wide
excision and skin grafting, did not have a
positive NAI.
Patients with Stage I, II or III
malignant melanoma who remained
cancer-free one year after tumour excision
had a decrease in their leucocyte response
to the melanoma extract within 8 months
after excision of the tumour (Fig. 4).
Hence the patients with Stage I and II
malignant melanoma showed LAI before
surgery, an immediate drop in the 2
weeks after surgery, followed by recovery
of LAI and then a diminution in LAI to
low NAI values by the 6th to 8th post-
operative month. In addition, a patient
with Stage III malignant melanoma
showed a similar LAI whein a solitary liver
metastasis (7 cm in diameter) from an
ocular melanoma was excised (Fig. 4).
By the 7th month, this patient's NAI had
fallen to a low value and clinically the
patient has no evideince of recurrent
cancer after 16 months.
In comparison, Fig. 5 shows the LAI
of 2 other patients, one with clinical Stage
TI malignant melanoma and the other
with early Stage ITT, who had their EAI
monitored. The patient with Stage TI
malignant melanoma had persistent LAI
after "curative" surgery. NAI of 75
eleven months after resection of his
tumour had decreased to 30 at the 12th
month and clinically the patient was free
of recurrent cancer. At 14 months,
however, there was evideince that the
patient had widespread visceral metas-
tasis and his leucocytes remained non-
reactive in the LAI assay. The other
patient had Stage III cancer and evidence
of minimal tumour burden when she was
initially tested. Also, the initial NAI was
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Fw(.i. 5. Sequential (letermliiationi of NAI of malignant melanoma patients where widespread v-isceral metastasis (WMAT) developed. Patient had Stage III melanoma with minimal tumour btirdlei ellinically when initially assayecl Patient had clinical Stage II melanoma when
first assayed1
low aind this is attributed to the local
irradiatioin and operation in the preceding
months. As the patient developed clinical
evidence of progressive and widespread
visceral metastases, the response of her
letucocytes in the LAI assay diminished.
Effects of chemnotherapy and imniunotherapy
on LAI
Two patients who received BCG
immuunotherapy had their LAI monitored
(Fig. 6). Both patients had Stage II
mnaligniant melanoma with recurrent
tumouLr in the lymph nodes draining the
original tumour site. Patient A showed
enhanced LAI with the development of a
recurrent tunmour in the subcutaneous
tissues draining the original tumour site.
After surgery the NAI fell, but the
administration of chemotherapy (DTIC)
impaired the uisual rise in the NAI. The
patient received DTIC once a month and
in the interval was scarified weekly with
BCG. The NAT remained depressed. By
the 4th month, recurrent tumour was
suspected and at the 5th month the
recurrence of malignant melanoma was
confirmed by a rapid increase in the size
of a nodule which was excised. A brief
but short-lived rise in the NAI occurred
after auto-immunization with irradiated
tumour cells (5 x 107 cells, 12,000 rad)
admixed with BCG intradermally. In
addition, this patient's response to dinitro-
chlorobenzene sensitization and to
cutaneous delayed hyper-sensitivity
testing with recall antigens was impaired
even before therapy. Patient B showed
the typical pattern of LAI before and
after surgery (Fig. 6). After recovery of
LAI, treatment of the patient with DTIC
chemotherapy depressed the leucocyte
response to melanoma antigen as assessed
by the tube LAI assay (Fig. 6). DTIC
was refused by the patient and subse-
quently the NAI rose. At the 4th month
the NAI had risen to 95, but fell to less
than 30 shortly after BCG scarification
was started. The NAI showed a slight
rise at the time of a subcutaneous recur-
rence, then fell again. At the 10th month
the NAI increased sharply and a month
later the patient had a seizure, secondary
to a solitary cerebral metastasis.
In these 2 patients, BCG scarification
did not enhance LAI by the melanoma
extract.
Melanoma antigen in asciticfluid
Ascitic fluid from a patient with
malignant melanoma metastasis in the
abdominal cavity was assayed for the
presence of antigenic activity. Ascitic
fluid, centrifuged at 2000 g to remove any
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FIG. 6. Sequential determination of NAI of 2 patients with melanoma Stage II who received chemo-
therapy and immunotherapy. Patient A demonstrated a rising LAI with recurrent tumour.
DTIC chemotherapy appeared to inhibit the recovery of LAI after surgery and also to impair the
rise in LAI with a second recurrence. Patient B showed a sharp fall in LAI after DTIC chemo-
therapy. Also, non-specific BCG immunotherapy appeared to diminish the LAI of PBL. A local
cutaneous recurrence appeared to be less stimulatory to systemic antitumour immunity than a
visceral metastasis. VM = visceral metastasis.
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cells, replaced the tumour extract as the
specific antigen, while the control non-
specific antigen remained the same.
Table IX shows that the leucocytes of a
reactive melanoma patient reacted to the
ascitic fluid and to the melanoma extract,
suggesting that the ascitic fluid from the
melanoma patient contained either parti-
culate or soluble melanoma antigen.
DISCUSSION
The results of this study indicate that
the LAI assay, modified for use in glass
test tubes (Tube LAI assay), is a simple
and quantitative method for measuring
anti-tumour immunity to malignant
melanoma. In agreement with the study
of Halliday et al. (1975), the tube LAI
assay for malignant melanoma appears to
be immunologically specific and repro-
ducible. Peripheral blood leucocytes of
20 out of 25 patients (80%) with active
malignant melanoma responded to an
extract of malignant melanoma with
significant leucocyte adherence inhibition,
whereas 4*500 of control subjects showed a
response. Anti-tumour immunity to the
malignant melanoma antigen as measured
by LAI was depressed by surgery and
chemotherapy. In contrast to the report
ofHalliday etal. (1975), melanoma patients
with a large tumour load exhibited
diminished or no LAI; moreover, in
"tumour-free " patients LAI to malignant
melanoma extract was not detectable 6-8
months after excision of the tumour.
The tube LAI assay is performed in
serumless medium. Koller et al. (1973)
showed that the majority of mononuclear
cells that adhere to glass or plastic, in the
absence of serum, are lymphocytes.
Both membrane markers and mitogen
response indicate that these lymphocytes
are a mixture of B and T cells. In the
present study we also observed that the
majority ofbuffy coat PBL adhered to the
glass in the absence of serum (protein).
Leucocytes from control subjects showed
non-specific non-adherence with the
addition of tumour extracts, and the
number of non-adherent cells (00 non-
adherence) was related to the protein
content of the extract. For this reason
it is essential in the tube LAI assay
carefully to titrate the different tumour
extracts and use a protein concentration
of each tumour extract that induces a
similar number of cells from control
subjects to be non-adherent, in the range
of 40-60 (20-30%) non-adherent cells.
In control subjects tumour extracts at
a protein concentration of 75 to 150 ,pg
produced this effect. In melanoma
patients the difference in leucocyte non-
adherence to the 2 tumour extracts was
also optimal at these protein concen-
trations.
The clear difference between patients
with malignant melanoma and control
donors, with or without other malignant
diseases, in the LAI by malignant
melanoma extract, strongly suggests that
the tube LAI assay detects a tumour
antigen of malignant melanoma. Con-
versely, the patients with malignant
melanoma did not respond to unrelated
tumour extracts, including those ofbreast,
ovary, lung and bladder cancers.
Malignant melanoma patients react
both to allogeneic and autologous malig-
nant melanoma extracts, and this
indicates that malignant melanoma shares
a common cross-reacting tumour antigen.
Although the present study has not
confirmed the presence of tumour-specific
transplantation antigens in individual
tumour extracts, they cannot be excluded.
Our studies on the isolation of the malig-
nant melanoma antigen indicate that the
cross-reacting antigen detected by the
tube LAI assay is on the cell surface
membrane (unpublished observations).
By contrast Lewis et al. (1969) showed, by
indirect membrane immunofluorescence,
that serum from melanoma patients
reacted against the autologous melanoma
cell surfaces and lacked significant cross-
reactivity with allogeneic melanoma.
Bodurtha et al. (1975), by a complement-
dependent cytotoxicity assay for anti-
bodies to malignant melanoma, confirmed
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the findings of Lewis et al. (1969). Other
investigators, however, have shown cross-
reactivity with membrane immuno-
fluorescence and cell-mediated assays
(Morton et al., 1968; Currie et al., 1971;
Nairn et al., 1972; Hellstrom et al., 1973;
and Hollinshead et al., 1974).
In the present study, it was shown that
serum from patients whose leucocytes
were reactive in the assay could " arm "
normal PBL to the appropriate tumour
extract. The serum factor was IgG
antibody. Moreover, in other studies
Grosser et al. (1976) have shown that the
reactive cell is phagocytic, glass-adherent
in the presence of serum and absence of
antigen, and has Fc cell-surface receptors.
Hence the LAI phenomenon is mediated
by peripheral blood monocytes " armed"
with cytophilic anti-tumour antibody.
The results of the present study
indicate that the anti-tumour immune
response of the malignant melanoma
patient was dependent on the extent ofthe
cancer, whereas Halliday et al. (1975) have
not reported any variation in LAI with
extent of disease. Patients with cancer
confined to the primary site had strong
responses and 11 out of 13 patients had a
positive NAI. Patients with regional
lymph node involvement (Stage II)
appeared to have an equally intense and,
in a few instances, even more intense LAI.
Patients with widely disseminated mela-
noma to the viscera had a markedly
impaired anti-tumour immune response
and 3 out of 5 patients had a negative
NAI. One of the 2 reactive patients with
Stage III cancer initially had a minimal
tumour burden and, as the tumour
burden increased, showed a loss of
reactivity. By other in vitro assays of
CMI or humoral immunity, a diminution
of tumour-specific immunity in melanoma
patients with disseminated disease has
been reported (Morton et al., 1968; Lewis
et al., 1969; Currie and Basham, 1972;
Cochran et al., 1973; Hellstrom et al.,
1973; Heppner et al., 1973; and Unsgaard
and O'Toole, 1975).
In this study, LAI was observed to be
depressed in malignant melainoma patients
with a large tumour burden involving their
viscera. Furthermore, by monitoring the
reactivity of PBL of malignant melanoma
patients, it was observed that leucocyte
response diminished as the tumour burden
increased. The lack of LAI in patients
with large tumour burdens is similar to the
observed depression ofin vrio anti-tumouir
immunity in experimental animal tumours
with increasing tumour burdens (Barski
and Youn, 1969; Coggin et al., 1974).
This suggests that the LAI assay in test
tubes may closely reflect the in vivo
anti-tumour immune status.
A hypothesis, based on ain experi-
mental animal tumour model, is that the
release of soluble tumour antigen locally
and systemically abrogates in vivo the
effector arm of the tumour immune
response and results in depressed in vitro
measurements of anti-tumour immunity
(Thomson, Eccles and Alexander, 1973;
Thomson et al., 1973; Coggin et al., 1974).
We suggested that soluble tumour antigen
in the microenvironment of the tumour
prevents rejection (Thomson, 1975) and,
as the tumour load increases, sufficient
tumour antigen is released systemically
to neutralize systemic anti-tumour
immunity. In the present study, this
hypothesis was supported by the finding
that particulate or soluble melanoma
a,ntigen was present in the tissue fluids
surrounding peritoneal metastasis.
Melanoma patients had their LAI
monitored before and after surgical
excision of their tumour. LAI was
profoundly depressed during the first 2
weeks after surgery. In a previous paper,
we reported the depression of LAI after
operation in breast cancer patients
(Grosser and Thomson, 1975). Slade et
al. (1975) showed that many aspects ofthe
immune system are depressed by surgery,
and Cochran, John and Gothoskar (1972)
reported that all melanoma patients had
reduced specific tumour immunity post-
operatively as measured by macrophage
migration inhibition, and reactivity
returned in most cases 6-22 days after
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operationi. Furthermnore in this study
chemotherapy with DTIC also depressed
the response ofleucocytes in the LAI assay.
The marked immunodepression ofanti-
tuimour immunity after surgery may be a
critical factor either in the establishment
or survival of meta,stases. At the time of
surgery, investigators have observed
circulating tumour cells in some patients,
but no difference in survival rates was
recorded between patients with or without
metastatic circulating tuimour cells
(Engell, 1959; Griffiths et al., 1973). In
an experimental animal tumour model,
Eccles and Alexander (1975) have shown
that, immunosuppressive therapy up to
onie month after surgical removal of the
primary tumour can increase the number
of metastases. Hence, animals seemingly
cured surgically- carry dormant tumour
cells that manifest themselves only after
treatments that are immunosuppressive.
Circulating tumour cells and/or metastatic
microfoci of tumour appear to be in a
delicate state of balance between survival
and rejection, and the depression of
anti-tumnour defences by surgery may
affect the host's cap'Lcity to destroy
residual tumour cells.
Most melanoma patients had a return
of LAI 1-3 months after surgical excision
of their tumouir. Tumour-free melanoma
patients tested at intervals showed a
decline in their anti-tumour immunitv
5-6 months post-surgery, and all had a low
or negative NAI by the 8th post-surgical
month. Among 8 tumour-free individuals
who were more than a year post-operative,
6 out of 8 tested had a NAI of 30 or less.
Although their mean NAI of 22 was below
the cut-off value of 30, it was higher than
the mean NAI of the control subjects.
WNrith their assay Maluish and Halliday
(1974) and Halliday et al. (I1975) have
noted no change in LAI in cancer-free"
patients during the year after tumour
excision. In the micro-cytotoxicity assay,
O'Toole et al. (1973) and Unsgaard and
O'Toole (1975) observed that removal of
tumours by surgery resulted in a loss of
detectable CMI in tumour-free patients
even one month after surgery, whereas
Hellstrom et al. (1973) reported that the
majority of clinically cured patients had
tumour-specific CMI during a 1-2-year
observation period after surgery.
Although LAI diminished after 6-8
months in tumour-free patients, the
pattern of LAI in those patients who
eventually manifested recurrent cancer
showed 2 different patterns. In one
instance, LAI remained elevated 11
months after " curative " surgery and fell
shortly before clinical evidence of
widespread visceral metastasis. The
other pattern showed a fall in LAI,
similar to that in patients who remained
cancer-free, with a, rise in LAI slightly
before local or limited visceral recurrence.
Holan et al. (1974) and Grosser and
Thomson (1975) reported that the addition
of serum directly in the tube LAI assay
either had a non-specific effect or no effect
at all. By contrast, Halliday et al. (1975)
and Maluish and Halliday (1974) have
reported that serum from early and late
tumour-bearers " blocks " the assay, and
serum from " cured " patients is frequently
unblocking". We have found that, by
pre-incubation of normal leucocytes with
serum from reactive patients with mela-
noma or breast cancer, and washing the
cells before plating them in the tube LAI
assay, immunologically specific " arming "
can be detected. These results are different
from those of Halliday et al. (1975) in that
serum from patients reactive in the assay
can " arm " normal leucocytes, and serum
from metastatic unreactive patients does
not " arm ". Moreover, serum from non-
reactive melanoma patients with large
tumour burdens can " block " the
reactivity of leucocytes from reactive
melanoma patients in the tube LAI assay
(Grosser and Thomson, 1976). The
blocking is immunologically specific and
therefore indicates that free antigenic
determinants must produce the effect,
since immune complexes bind to lympho-
cytes annd monocytes non-specifically.
The LAI assays performed on haemo-
cytometers (Hallidav and Miller, 1972)
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and in test tubes (Holan et al., 1974;
Grosser and Thomson, 1975) appear to
differ only methodologically; nevertheless,
important differences in the results are
observed. Holan (1975) has also observed
a weaker LAI in rats with large pro-
gressively growing tumours than in rats
with small regressing tumours. The
explanation for the difference in results is
not readily apparent but may be related
to the difference in incubation conditions.
The ease and rapidity of performing
the tube LAI assay and its reproducibility
make it useful to monitor the anti-
tumour immune response. The changes
observed in PBL reactivity in the LAI
assay have diagnostic potential when
correlated with detailed clinical know-
ledge of the patient. Moreover, since the
changes in LAI reflect the patient's
clinical status, the need for performing
blocking and unblocking studies is less
necessary. This is important, since a
constant source of reactive leucocytes is
frequently neither available nor practical.
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